Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report

Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report

Abstract Background Sporadic lymphangioleiomyomatosis (LAM) is a rare form of diffuse parenchymal lung disease. PD-1 blocking antibodies constitute an essential treatment option for advanced non-small-cell lung cancer (NSCLC). The effect of immune checkpoint inhibitors in lymphangioleiomyomatosis pa...

Full description

Bibliographic Details
Main Authors: Johan Pluvy, Solenn Brosseau, Sandrine Stelianides, Claire Danel, Marina Nguenang, Antoine Khalil, Bruno Crestani, Gérard Zalcman, Valérie Gounant
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Pulmonary Medicine
Subjects:
NSCLC
Sporadic lymphangioleiomyomatosis
Adenocarcinoma
Nivolumab
Immune checkpoint inhibitors
Online Access:http://link.springer.com/article/10.1186/s12890-018-0775-5

Internet

http://link.springer.com/article/10.1186/s12890-018-0775-5

Similar Items